Establishing a Long Island Bioscience Hub

 描述(由申请者提供)：通过开发、转化和商业化我们学术机构的生物医学研究事业产生的基本发现，学术部门存在着促进人类健康的特殊机会。不幸的是，创新的确定、转化、开发和最终商业化的过程仍然远远不是最优的，使该地区智力资本的全部经济和社会利益得不到实现。为了满足这一需求，我们提议建立一个区域伙伴关系，由石溪大学(SBU)、冷泉港实验室(CSHL)和布鲁克海文国家实验室(BNL)组成。这些机构展示了生物科学创新的能力，这些创新推动了生物医学科学的进程，并通过FDA批准的疗法，包括ReoPro(注册商标)、SAFHS(注册商标)、XIAFLEX(注册商标)、Periostat(注册商标)和Oracea(注册商标)，新型医疗设备，包括3D-虚拟结肠镜检查和LivMD(注册商标)，以及新成立的公司，包括新英格兰生物实验室、OSI制药公司、Collagenex、Pharmacopeia、Exogen和Set Point Medical，为改善医疗保健做出了贡献。通过四个具体目标，州(SBU)、私营(CSHL)和联邦(BNL)的伙伴关系将建立在转化式生物医学研究和商业化方面的现有优势基础上：A)开发基础设施和实施系统；B)增加我们基础生物医学研究企业内部新的医疗创新的产量；C)推动扎根于该地区的新生物技术、制药和医疗器械公司的形成；以及D)培养下一代生物企业家来领导这些企业。总的来说，这些目标将为一个充满活力的生物科学产业集群奠定基础，该产业集群将培育一个不断扩大的长岛生物科学中心(LIBH)。

 DESCRIPTION (provided by applicant): An exceptional opportunity exists within the academic sector to promote human health through the development, translation and commercialization of basic discoveries which arise from the biomedical research enterprise of our academic institutions. Unfortunately, the process by which innovations are identified, translated, developed, and ultimately commercialized is still far from optimal, leaving the full economic and societal benefit from the region's intellectual capital unrealized. To address this need, we propose to form a regional partnership comprised of Stony Brook University (SBU), Cold Spring Harbor Laboratory (CSHL) and Brookhaven National Laboratory (BNL). These institutions have a demonstrated capacity for bioscience innovation that has advanced the course of biomedical science and contributed to improved healthcare through FDA approved therapies including ReoPro(r), SAFHS(r), Xiaflex(r), Periostat(r) and Oracea(r), new medical devices including 3D- virtual colonoscopy and LivMD(r), and new company formation including New England BioLabs, OSI Pharmaceuticals, Collagenex, Pharmacopeia, Exogen and Set Point Medical. Through four specific aims, this State (SBU), Private (CSHL) and Federal (BNL) partnership will build upon existing strengths in translational biomedical research and commercialization to: A) Develop an infrastructure and implementation system, B) Increase the yield of new healthcare innovations from within our basic biomedical research enterprise, C) Fuel new biotech, pharma and medical device company formation rooted within the region, and D) Train next generation bio-entrepreneurs to lead these ventures. In aggregate, these objectives will provide the foundation for a vibrant bioscience industry cluster that will foster an ever-expanding Long Island Bioscience Hub (LIBH).